How Addictive Is Codeine? Risks and Withdrawal

Codeine is a genuine opioid, and it carries a real risk of addiction, though that risk is lower than what you’d face with stronger opioids like oxycodone or morphine. The drug works by converting into morphine inside your liver, which means its addictive potential comes from the same brain pathways that make other opioids habit-forming. What makes codeine tricky is that many people underestimate it because it’s widely available, sometimes without a prescription, and its reputation as a “mild” painkiller can mask the fact that dependence develops through the same biological machinery as dependence on any other opioid.

How Codeine Actually Works in Your Body

Codeine itself is not especially active. It acts as a prodrug, meaning your body has to convert it into something else before it does much. That something else is morphine. An enzyme in your liver called CYP2D6 handles this conversion, turning codeine into morphine, which then binds to opioid receptors in the brain and produces pain relief, sedation, and the mild euphoria that makes repeated use appealing.¹ This is the same receptor system activated by heroin, fentanyl, and prescription painkillers, just at a lower intensity for most people taking standard codeine doses.

The fact that codeine must be converted before it works introduces a wrinkle that affects both its pain-relieving ability and its addiction risk: not everyone converts it at the same rate. Your genetic makeup determines how much CYP2D6 enzyme you produce, and this varies enormously across individuals.

Why Your Genetics Change the Equation

People fall into rough categories based on how efficiently they metabolize codeine. Most people are “normal” metabolizers who convert a predictable fraction of each dose into morphine. But roughly 5 to 10 percent of people of European ancestry are “poor metabolizers” who barely convert codeine at all, meaning the drug gives them almost no pain relief and very little opioid effect. At the other end of the spectrum, “ultrarapid metabolizers” carry extra copies of the CYP2D6 gene and flood their systems with morphine from a standard dose.²

For ultrarapid metabolizers, a normal prescription dose can produce dangerously high morphine levels. This matters for addiction risk in two ways. First, these individuals experience stronger euphoria from the same dose, which can reinforce the desire to keep taking the drug. Second, the elevated morphine levels create a steeper tolerance curve, meaning the body adjusts faster and the person needs more codeine sooner to get the same effect. Drug surveillance has documented cases of unexpected respiratory depression and death in children who turned out to be ultrarapid metabolizers, which led the American Academy of Pediatrics to recommend against codeine use in children.³

The prevalence of ultrarapid metabolism varies by ethnicity. It’s more common in some North African and Middle Eastern populations, where rates can exceed 20 percent, than in Northern European populations. If you’ve ever taken codeine and felt unusually drowsy or euphoric, or conversely felt nothing at all, your CYP2D6 status is a likely explanation.

How Dependence Develops

Codeine dependence follows the same general pathway as dependence on other opioids. When morphine (produced from codeine in your liver) repeatedly activates opioid receptors in the brain, those receptors gradually become less responsive. At the cellular level, repeated stimulation of the receptor triggers chemical changes that dampen the signal, a process researchers have traced to specific enzymes that modify receptor behavior.⁴ The practical result is tolerance: the same dose stops working as well, and you need more to get the same relief or the same feeling.

Tolerance alone isn’t addiction, but it’s the gateway. As your body adapts to regular opioid stimulation, it also recalibrates its baseline. Without the drug, you feel worse than you did before you started taking it. That gap between your new, lowered baseline and normal functioning is what drives continued use, even when you’d prefer to stop. The brain’s reward circuitry, particularly dopamine pathways, also gets involved, creating psychological cravings on top of the physical need.

What distinguishes codeine from stronger opioids is the ceiling on how much morphine your liver can produce from it. There’s a practical limit to how high blood morphine levels can climb from codeine alone, which is why codeine dependence tends to escalate more slowly than dependence on drugs like oxycodone or heroin. But “more slowly” doesn’t mean “never.” People who use codeine daily for weeks to months can and do develop full physical dependence.

Who Is Most at Risk

Research on codeine dependence consistently identifies a few recurring risk factors. A large retrospective study of chronic pain patients found that younger age (40 or under), existing mental health conditions, concurrent use of anti-anxiety medications like benzodiazepines, and a history of using stronger opioids all significantly raised the likelihood of problematic codeine use.⁵ The mental health connection is worth noting: systematic reviews have found that people who become dependent on codeine often report that their codeine use escalated in response to psychiatric symptoms like anxiety or depression, not just pain.⁶

This pattern makes sense when you consider that opioids don’t just dull pain; they also temporarily relieve emotional distress. Someone managing both chronic pain and untreated anxiety has two reasons to reach for codeine, and the emotional relief can be just as reinforcing as the physical relief. The opioid epidemic has made clinicians much more aware of this overlap, but it remains underappreciated among people who think of codeine as a harmless step above ibuprofen.

What Codeine Withdrawal Feels Like

Codeine withdrawal produces the classic opioid withdrawal syndrome, though typically milder than withdrawal from stronger opioids. Symptoms usually begin 12 to 24 hours after the last dose and peak around 48 to 72 hours. They include muscle aches, restlessness, anxiety, sweating, runny nose, watery eyes, diarrhea, nausea, and insomnia. The experience is often compared to a bad flu with added anxiety and irritability.

The physical symptoms generally resolve within a week, though sleep disturbances and mood changes can linger for several weeks. The psychological component, particularly cravings and a low-grade sense of unease, often outlasts the physical symptoms and is the main driver of relapse.

One encouraging finding from clinical research: patients with problematic codeine use can be weaned off the drug without their pain spiraling out of control. A study of patients undergoing supervised codeine reduction found that average daily codeine use dropped from roughly 237 mg to about 45 mg after treatment and stayed near that level at follow-up, without significant increases in pain or decreases in quality of life.⁷ This undercuts a common fear among people dependent on codeine: that stopping the drug will leave them in unbearable pain. For many, the pain was being amplified by the dependence cycle itself.

The Hidden Danger of Combination Products

Codeine is rarely sold on its own. It’s usually combined with acetaminophen (paracetamol) or ibuprofen in over-the-counter or prescription formulations. This creates a serious problem when someone with codeine dependence starts taking escalating doses, because the non-opioid ingredient can cause severe harm long before the codeine dose becomes lethal.

A study of patients presenting for codeine withdrawal treatment found alarming rates of complications from the non-opioid component. Patients taking ibuprofen-codeine combinations fared worse: about 87 percent had complications, compared with 65 percent of those on acetaminophen-codeine products. The ibuprofen group had higher rates of gastrointestinal bleeding, anemia, and kidney problems. There were two deaths in the ibuprofen-codeine group.⁸

This is one of the more underappreciated risks of codeine dependence. A person escalating their intake to chase the opioid effect is simultaneously taking dangerous quantities of a drug they aren’t even thinking about. High-dose acetaminophen destroys the liver; high-dose ibuprofen eats through the stomach lining and damages the kidneys. In countries where codeine combinations were available over the counter, these “silent” injuries often brought patients to medical attention before the opioid dependence itself did.

Codeine in Pregnancy

Codeine use during pregnancy can cause the newborn to go through opioid withdrawal after birth, a condition known as neonatal opioid withdrawal syndrome. Even codeine-containing analgesics taken for something as common as headaches during pregnancy have been linked to this outcome.⁹

A large study comparing different opioids used during pregnancy found that codeine was associated with a lower risk of neonatal withdrawal than hydrocodone, with about a 43 percent lower relative risk in adjusted models.¹⁰ That’s somewhat reassuring compared with stronger opioids, but the risk is not zero. About 2 percent of newborns exposed to opioids in that study developed withdrawal symptoms. The takeaway is that codeine during pregnancy should be treated as a genuine opioid exposure, not as something you can take casually just because it’s available in lower-tier pain medications.

“Lean” and Recreational Codeine Culture

Codeine’s relatively mild reputation has given it a distinct niche in recreational drug culture. The most prominent example is “lean” or “purple drank,” a mixture of codeine-promethazine cough syrup with soda, sometimes with added candy. The combination produces sedation and mild euphoria, and it has been glamorized extensively in hip-hop music and broader popular culture, often displayed in a signature double Styrofoam cup.¹¹ A systematic review of the phenomenon noted that rap artists have promoted its tranquilizing and euphoric effects through music and videos for years.¹²

The addition of promethazine, an antihistamine with sedating properties, intensifies the drowsy high but also increases the danger. Promethazine itself has been linked to a striking number of fatalities: an analysis of European adverse drug reaction reports found that over half of promethazine abuse cases involved deaths, mostly classified as drug toxicity, with opioids being the most commonly co-reported drugs.¹³ Lean is not a gentle recreational experience, no matter how casually the culture presents it.

Codeine and Drug Testing

If you take codeine and then undergo a drug test, you will likely test positive for opiates. This is expected, since your body converts codeine into morphine. But it creates a practical problem: both codeine (a legal prescription drug) and heroin (an illegal drug) produce morphine as a metabolite. Standard workplace urine screens cannot easily distinguish between the two.¹⁴

More sophisticated testing can help. The ratio of morphine to codeine in blood or urine provides a clue: codeine users tend to have relatively more codeine and less morphine, while heroin users show high morphine with only trace codeine (since heroin itself can contain small amounts of codeine as an impurity). If you’re taking prescribed codeine and face a drug test, having your prescription documentation readily available is the practical safeguard.

What Happened When Australia Required Prescriptions

Until February 2018, Australians could buy low-dose codeine combinations over the counter at pharmacies. When Australia rescheduled codeine to prescription-only, it created a natural experiment in how access shapes use and harm. The results were striking: monthly codeine-related poisonings dropped by about half, and over-the-counter codeine sales fell by roughly 87 percent. There was no compensatory increase in sales of higher-strength codeine products or other opioids.¹⁵

A follow-up study tracked what happened to people who had been regular codeine users before the policy change. Their average daily doses of both paracetamol and ibuprofen dropped significantly over the following year, suggesting they weren’t simply replacing codeine with massive quantities of other painkillers.¹⁶ This is important because it addresses the main objection to restricting access: that people in pain will just switch to something else potentially harmful. Many people, it turns out, were taking codeine not because they truly needed it but because it was there. Remove the easy access and a significant number simply use less of everything.

The Stigma Problem

People who develop codeine dependence often face a particular kind of stigma, partly because codeine occupies an awkward middle ground between “real” opioids and everyday pain relief. Qualitative research on people living with chronic pain has documented how the broader opioid crisis has changed the social landscape for anyone taking opioids, even prescribed ones. Patients report increased worry from family members about the dangers of opioids, prejudice and discrimination during conversations about their pain treatment, and a felt need to either advocate for themselves or hide their opioid use entirely.¹⁷

For codeine-dependent individuals specifically, this stigma can be compounded by the perception that codeine is too weak to cause “real” addiction. Friends and family may dismiss the problem, and the person themselves may struggle to recognize their dependence as legitimate. When your drug of dependence is sold next to the vitamins in a pharmacy, it’s psychologically harder to accept that you have a problem that warrants treatment. This delay in recognition is one of the reasons codeine dependence often progresses further than it should before someone seeks help, and why the combination-product injuries described earlier are so common by the time patients present to a doctor.

Codeine Versus Other Opioids for Pain

One question worth addressing is whether codeine even works well enough to justify its risks. Research comparing codeine-acetaminophen with oxycodone-acetaminophen for short-term pain after emergency department visits found that the two performed similarly for pain relief, which surprised the investigators. The authors noted that codeine combinations, being less tightly regulated as a Schedule III agent compared to oxycodone’s Schedule II status, might be a reasonable alternative with a lower misuse profile.¹⁸

This finding doesn’t mean codeine is safe or addiction-free. It means that for short-term pain, you may not need to reach for a stronger opioid when codeine does a comparable job. The tradeoff matters from a public health perspective: prescribing the weakest effective opioid limits exposure to drugs with higher addiction ceilings, even if the weaker drug still carries its own risks. For the individual patient, the relevant question is whether any opioid is necessary at all, or whether non-opioid alternatives would be adequate. For many common pain scenarios, they are.